HB 1730 Cancer Drug Parity Act of 2019

About HB-1730

Requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are

• (1) approved by the Food and Drug Administration;
• (2) medically necessary for the cancer treatment; and
• (3) clinically appropriate in terms of type, frequency, extent site, and duration.To comply with this requirement, health plans may not, with respect to anticancer medications
• (1) change or replace benefits to increase out-of-pocket costs,
• (2) reclassify benefits to increase costs, or
• (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.